GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IRLAB Therapeutics AB (OSTO:IRLAB A) » Definitions » Equity-to-Asset

IRLAB Therapeutics AB (OSTO:IRLAB A) Equity-to-Asset : 0.56 (As of Mar. 2024)


View and export this data going back to 2017. Start your Free Trial

What is IRLAB Therapeutics AB Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. IRLAB Therapeutics AB's Total Stockholders Equity for the quarter that ended in Mar. 2024 was kr76.75 Mil. IRLAB Therapeutics AB's Total Assets for the quarter that ended in Mar. 2024 was kr136.67 Mil.

The historical rank and industry rank for IRLAB Therapeutics AB's Equity-to-Asset or its related term are showing as below:

OSTO:IRLAB A' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.48   Med: 0.91   Max: 0.97
Current: 0.56

During the past 11 years, the highest Equity to Asset Ratio of IRLAB Therapeutics AB was 0.97. The lowest was 0.48. And the median was 0.91.

OSTO:IRLAB A's Equity-to-Asset is ranked worse than
59.88% of 1558 companies
in the Biotechnology industry
Industry Median: 0.67 vs OSTO:IRLAB A: 0.56

IRLAB Therapeutics AB Equity-to-Asset Historical Data

The historical data trend for IRLAB Therapeutics AB's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IRLAB Therapeutics AB Equity-to-Asset Chart

IRLAB Therapeutics AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.87 0.94 0.85 0.90 0.65

IRLAB Therapeutics AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.83 0.81 0.79 0.65 0.56

Competitive Comparison of IRLAB Therapeutics AB's Equity-to-Asset

For the Biotechnology subindustry, IRLAB Therapeutics AB's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IRLAB Therapeutics AB's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IRLAB Therapeutics AB's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where IRLAB Therapeutics AB's Equity-to-Asset falls into.



IRLAB Therapeutics AB Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

IRLAB Therapeutics AB's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=115.764/177.121
=0.65

IRLAB Therapeutics AB's Equity to Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

Equity to Asset (Q: Mar. 2024 )=Total Stockholders Equity/Total Assets
=76.745/136.667
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


IRLAB Therapeutics AB  (OSTO:IRLAB A) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


IRLAB Therapeutics AB Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of IRLAB Therapeutics AB's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


IRLAB Therapeutics AB (OSTO:IRLAB A) Business Description

Traded in Other Exchanges
Address
Arvid Wallgren Backe 20, Goteborg, SWE, 413 46
IRLAB Therapeutics AB is a drug discovery and development company providing novel treatments for disorders of the brain. The company focuses on innovative treatments and quality of life for patients with neurological and psychiatric illnesses. It is engaged in programs targeting core dysfunctions in Parkinson's disease and dementias. In addition, it is also involved in the clinical development of novel compounds which aims at offering improved clinical benefit for patients with Parkinson's disease. The company's current clinical candidates, mesdopetam (IRL790) and pirepemat (IRL752), both of which have successfully gone through Phase I safety and Phase IIa efficacy proof-of-concept studies, are now in Phase IIb trials.

IRLAB Therapeutics AB (OSTO:IRLAB A) Headlines

No Headlines